Oncology research usually needs to work across multiple disciplines to reveal the mechanisms leading to cancer. Oncology research may include integrated transcriptomics, proteomics, metabolomics, oncogenic signals, epigenetics or immune evasion. Studies in these areas have revealed new features of cancer and emerging targets leading to therapeutic resistance, such as CD9.
We work with experts and biopharmaceutical companies to understand the current and future needs of this field. With the impact of these partnerships on our pipeline, we can develop more comprehensive validation reagents for identified and new cancer targets.
